Tauroursodeoxycholic acid inhibits intestinal inflammation and barrier disruption in mice with non-alcoholic fatty liver disease.

Weijun WangJinfang ZhaoWenfang GuiDan SunHaijiang DaiLi XiaoHuikuan ChuFan DuQingjing ZhuBernd SchnablKai HuangLing YangXiaohua Hou

Published in: British journal of pharmacology (2018)

TUDCA attenuates the progression of HFD-induced NAFLD in mice by ameliorating gut inflammation, improving intestinal barrier function, decreasing intestinal fat transport and modulating intestinal microbiota composition.

Keyphrases

oxidative stress
high fat diet induced
adipose tissue
diabetic rats
high glucose
signaling pathway
type diabetes
insulin resistance
fatty acid
endothelial cells
skeletal muscle
metabolic syndrome
drug induced
liver fibrosis